KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for Inovio Pharmaceuticals (INO) over the last 14 years, with Q2 2022 value amounting to $56935.0.

  • Inovio Pharmaceuticals' Non-Current Deffered Revenue fell 2069.01% to $56935.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $56935.0, marking a year-over-year decrease of 2069.01%. This contributed to the annual value of $64361.0 for FY2021, which is 1875.05% down from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Non-Current Deffered Revenue of $56935.0 as of Q2 2022, which was down 2069.01% from $60648.0 recorded in Q1 2022.
  • In the past 5 years, Inovio Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $9.0 million in Q1 2018 and a low of $56935.0 during Q2 2022
  • Its 5-year average for Non-Current Deffered Revenue is $2.0 million, with a median of $93497.5 in 2020.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Non-Current Deffered Revenue skyrocketed by 2876.25% in 2018, and later tumbled by 9880.76% in 2019.
  • Over the past 5 years, Inovio Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $8.5 million in 2018, then crashed by 98.81% to $101567.0 in 2019, then decreased by 22.01% to $79214.0 in 2020, then dropped by 18.75% to $64361.0 in 2021, then fell by 11.54% to $56935.0 in 2022.
  • Its last three reported values are $56935.0 in Q2 2022, $60648.0 for Q1 2022, and $64361.0 during Q4 2021.